medigraphic.com
ISSN 2594-3006 (Digital)
ISSN 2007-1752 (Impreso)
Archivos de Medicina de Urgencia de México

2024, Número 1

<< Anterior Siguiente >>

Arch Med Urg Mex 2024; 16 (1)


Fisiopatología de la preeclampsia placentaria

Cruz-Martínez FJ

Idioma: Español
Referencias bibliográficas: 71
Paginas: 37-44
Archivo PDF: 245.37 Kb.


RESUMEN

La preeclampsia es una patología interesante desde el punto de vista fisiopatológico. En este artículo expondré los mecanismos que participan en el desarrollo de la preeclampsia placentaria, que es la primera etapa de varias que rigen la preeclampsia de aparición temprana. En el artículo se describe la participación de los múltiples mecanismos que interactúan para ocasionar el proceso de mala placentación. Describiré la participación de los componentes inmunológicos y no inmunológicos, entre ellos macrófagos, neutrófilos, células dendríticas, asesinas naturales, antígenos leucocitarios humanos, Linfocitos T (CD4, TH-17 y reguladores), equilibrio TH1/TH2, disfunción endotelial por enfermedades crónico degenerativas, que participan en la remodelación anómala de las arterias uterinas que desemboca en una hipoperfusión uteroplacentaria que lleva a fenómenos complejos de apoptosis, necrosis y aponecrosis, que sirven de sustrato para que se dé la secreción de las micropartículas que serán las desencadenantes de las manifestaciones clínicas en la madre.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Melchiorre K, Giorgione V, Thilaganathan. The placenta andpreeclampsia: villain or victim? Am J Obstet Gynecol. 2022 Feb; 226(2S):S954-S962. doi: 10.1016/j.ajog.2020.10.024.

  2. Roberts JM, Catov JM. Preeclampsia more than 1 disease: or isit? Hypertension. 2008 Apr;51(4):989-90. doi: 10.1161/HYPERTENSIONAHA.107.100248.

  3. Gonzáles-Merlo J, Gonzáles E, Fabre E. Obstetricia. Elseiver.2018.

  4. Christopher W. G. Redman, Ian L. Sargent. Inmunology ofPre-Eclampsia. American Journal of Reproductive Immunology2010; 63: 534-543.

  5. Robillard PY, Hulsey TC. Association of pregnancyinduced-hypertension,pre-eclampsia, and eclampsia with duration of sexual cohabitationbefore conception. Lancet 1996; 347: 619.

  6. Kho EM, McCowan LM, North RA, et al. On behalf of the SCOPEConsortium: duration of sexual relationship and its effect onpreeclampsia and small for gestational age perinatal outcome. JReprod Immunol 2009; 82: 66–73.

  7. Zhang J, Patel G: Partner change and perinatal outcomes. a systematicreview. Paediatr Perinat Epidemiol 2007; 21(1): 46–57.

  8. Basso O, Christensen K, Olsen J. Higher risk of Preeclampsia afterchange of partner. An effect of longer interpregnancy intervals?Epidemiology 2001; 12: 624–629.

  9. Tubbergen P, Lachmeijer AM, Althuisius SM, Vlak ME, van GeijnHP, Dekker GA. Change in paternity: a risk factor for preeclampsiain multiparous women? J Reprod Immunol 1999; 45: 81–88.

  10. Skjaerven R, Wilcox AJ, Lie RT. The interval between pregnanciesand the risk of preeclampsia. N Engl J Med 2002; 346: 33–38.

  11. Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriageto preeclampsia. J Soc Gynecol Investig 2004; 11: 342–352.

  12. Wilczynski JR. Immunological analogy between allograft rejection,recurrent abortion and preeclampsia the same basic mechanism?Hum Immunol 2006; 67: 492–511.

  13. Billington WD. The immunological problem of pregnancy. 50 yearswith the hope of progress. A tribute to Peter Medawar. J ReprodImmunol 2003; 60: 1–11.

  14. Saito S, Sakai M, Sasaki Y, Nakashima A, Shiozaki A. inadequatetolerance induction may induce preeclampsia. J Reprod Immunol2007; 76: 30–39.

  15. Rajagopalan S, Long EO. Understanding how combinations ofHLA and KIR genes influence disease. J Exp Med 2005; 201:1025–1029.

  16. Hiby SE, Walker JJ, O’Shaughnessy KM, et al. Combinations ofmaternal KIR and fetal HLA-C genes influence the risk of preeclampsiaand reproductive success. J Exp Med 2004; 200: 957–965.

  17. Hiby SE, Regan L, Lo W, Farrell L, Carrington M, Moffett A. Associationof maternal killer-cell immunoglobulin-like receptors andparental HLA-C genotypes with recurrent miscarriage. Hum Reprod2008; 23: 972–976.

  18. Tilburgs T, Scherjon SA, van der Mast BJ, et al. Fetal-maternalHLA-C mismatch is associated with decidual T cell activation andinduction of functional T regulatory cells. J Reprod Immunol 2009;82: 148–157.

  19. Sun JC, Lanier LL. Natural killer cells remember: an evolutionarybridge between innate and adaptive immunity? Eur J Immunol

  20. 2009; 39: 2059–2064.20. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific controlof inflammation by TLR-induced chromatin modifications. Nature2007; 447: 972–978.

  21. Mellor AL, Munn DH. Creating immune privilege. active local suppressionthat benefits friends, but protects foes. Nat Rev Immunol2008; 8: 74–80.

  22. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatoryT cells and blocks their conversion into Th17-like T cells. JImmunol 2009; 183: 2475–2483.

  23. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetalrejection by tryptophan catabolism. Science 1998; 281: 1191–1193.

  24. Nishizawa H, Hasegawa K, Suzuki M, et al. Mouse model forallogeneic immune reaction against fetus recapitulates humanpre-eclampsia. J Obstet Gynaecol Res 2008; 34: 1–6.

  25. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss III JF,Petraglia F: Inflammation and pregnancy. Reprod Sci 2009; 16:206–215.

  26. Chaouat G. Regulation of T-cell activities at the fetoplacental interface—by placenta? Am J Reprod Immunol. 1999;42:199-204.

  27. Rustveld LO, Kelsey SF, Sharma R: Association between maternalinfections and preeclampsia: a systematic review of epidemiologicstudies. Matern Child Health J 2008; 12:223–242.

  28. Caretto D, Katzman SD, Villarino AV, Gallo E, Abbas AK: Cuttingedge: the Th1 response inhibits the generation of peripheral regulatoryT cells. J Immunol 2010; 184:30–34.

  29. Abrahams VM. Mechanisms of antiphospholipid antibody-associatedpregnancy complications. Thromb Res 2009; 124: 521–525.

  30. Dechend R, Muller DN, Wallukat G, Homuth V, Krause M, DudenhausenJ, et al. Activating autoantibodies against the AT1 receptorin preeclampsia. Autoimmun Rev 2005; 4: 61–65.

  31. Zhou CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonisticautoantibodies induce pre-eclampsia in pregnant mice. Nat Med2008; 14: 855–862.

  32. Herse F, Verlohren S, Wenzel K, et al. Prevalence of agonisticautoantibodies against the angiotensin II type 1 receptor and solublefms-like tyrosine kinase 1 in a gestational age-matched casestudy. Hypertension 2009; 53: 393–398.

  33. Méndez JD, Xie J, Aguilar-Hernández M, Méndez-Valenzuela V.Trends in advanced glycation end products research in diabetesmellitus and its complications. Mol Cell Biochem 2010; 341: 33-41.

  34. Lahera V, Cediel E, de las Heras N, et al. Alteraciones del endotelioen la hipertensión 2003; 23(4): 3-12.

  35. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteriesin the pathogenesis of Preeclampsia. Obstet Gynecol Annu1972; 1: 177–191.

  36. Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal Placentation,Angiogenic Factors, and the Pathogenesis of PreeclampsiaObstet Gynecol Clin 2010; 37: 239–253.

  37. Ambreen A, Harrison A, Harrison M. Preeclampsia: Systemic EndothelialDamage Leading to Increased Activation of The BloodCoagulation Cascade. Journal of Biotech Research 2012; 4: 26-43

  38. Ortega MA, Fraile-Martínez O, García-Montero C, et al. The PivotalRole of the Placenta in Normal and Pathological Pregnancies:A Focus on Preeclampsia, Fetal Growth Restriction, and MaternalChronic Venous Disease. Cells. 2022 Feb 6;11(3):568. doi:10.3390/cells11030568.

  39. Ahn H, Park J, Gilman-Sachs A, Kwak-Kim J. Immunologic characteristicsof preeclampsia, a comprehensive review. Am JReprod Immunol. 2011 Apr;65(4):377-94. doi: 10.1111/j.1600-0897.2010.00913.x.

  40. Gebara N, Correia Y, Wang K, Bussolati B. Angiogenic Propertiesof Placenta-Derived Extracellular Vesicles in Normal Pregnancyand in Preeclampsia. Int J Mol Sci. 2021 May; 22(10): 5402. doi:10.3390/ijms22105402.

  41. Ferrara N. Vascular endothelial growth factor: basic science andclinical progress. Endocr Rev 2004; 25: 581–611.

  42. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A (164/165) and PlGF:roles in angiogénesis and arteriogenesis. Trends Cardiovasc Med2003; 13(5): 169–175.

  43. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptorsin regulation of angiogenesis and lymphangiogenesis. ExpCell Res 2006; 312(5): 549–560.

  44. Takahashi H, Shibuya M. The vascular endothelial growth factor(VEGF)/VEGF receptor system and its role under physiological andpathological conditions. Clin Sci (Lond) 2005; 109(3): 227–241.

  45. Maynard SE, Min JY, Merchan J, et al. Excess placental solublefms-like tyrosine kinase 1 (sFlt1) may contribute to endothelialdysfunction, hypertension, and proteinuria in preeclampsia. J ClinInvest 2003; 111(5): 649–658.

  46. Nagamatsu T, Fujii T, Kusumi M, et al. Cytotrophoblasts up-regulatesoluble fmslike tyrosine kinase-1 expression under reducedoxygen: an implication for the placental vascular developmentand the pathophysiology of preeclampsia. Endocrinology 2004;145(11): 4838–4845.

  47. Shore VH, Wang TH, Wang CL, et al. Vascular endothelial growthfactor, placenta growth factor and their receptors in isolated humantrophoblast. Placenta 1997; 18(8): 657–665.

  48. Gu Y, Lewis DF, Wang Y. Placental productions and expressions ofsoluble endoglin, soluble fms-like tyrosine kinase receptor-1, andplacental growth factor in normal and preeclamptic pregnancies. JClin Endocrinol Metab 2008; 93(1): 260–266.

  49. Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of preeclampsia.Curr Opin Nephrol Hypertens. 2015 Mar;24(2):131-8.doi: 10.1097/MNH.0000000000000105.

  50. Gupta S, Agarwal A, Sharma R. The rol of placental oxidativestress and lipid peroxidation in preeclampsia. Obstet GynecolSurv 2005; 60: 807-816.

  51. Raijmakers M, Dechend R, Poston L. Oxidative stress and preeclampsia.rationale for antioxidant clinical trials. Hypertension2004; 44: 374-380.

  52. Lizarbe MI. El suicidio y la muerte celular. Revista de la Real Academiade Ciencias Exactas, Físicas y Naturales (Esp) 2007; 101: 1-33.

  53. Huppertz B, Herrler A. Regulation of proliferation and apoptosisduring development of the preimplantattion embryo and the placenta.Birth Def Res (part C) 2005;75:249-61.

  54. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview ofcell death. Am J Pathol 1995; 146: 3-15.

  55. Lunetta P, Penttila A. Immunohistochemical identification of syncytiotrophoblasticcells and megakaryocytes in pulmonary vesselsin a fatal case of amniotic fluid embolism. Int J Legal Med 1996;108: 210-4.

  56. Huppertz B, Kadyrov M, Kigdom JC. Apoptosis and its role in thetrophoblast. Am J Obstet Gynecol 2006; 195: 29-39.

  57. 57 Knight M, Redman CW, Linton EA, Sargent IL. Shedding ofsyncytiotrophoblast microvilli into the maternal circulation inpre-eclamptic pregnancies. Br J Obstet Gynaecol 1998; 105(6):632-640.

  58. Johansen M, Redman CW, Wilkins T, Sargent IL. Trophoblast deportationin human pregnancy---its relevance for pre-eclampsia.Placenta1999; 20: 531-539.

  59. Formigli L, Papucci L, Tani A, et al. Aponecrosis: morphologicaland biochemical exploration of a syncretic process of cell deathsharing apoptosis and necrosis. J Cell Physiol 2000; 182: 41-49.

  60. Levy R, Smith SD, Chandler K, Sadovsky Y, Nelson DM. Apoptosisin human cultured trophoblasts is enhanced by hypoxia anddiminished by epidermal growth factor. Am J Physiol Cell Physiol2000; 278: C982-C988.

  61. Tjoa ML, Cindrova-Davies T, Spasic-Boskovic O, Bianchi DW,Burton GJ. Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. Am J Pathol 2006; 169: 400-404.

  62. Straszewski S, Abrahams V, Mor G. The role of apoptosis in theregulation of trophoblast survival and differentiation during pregnancy.Endocrine Rev 2005; 26: 877-897.

  63. Smarason AK, Sargent IL, Starkey PM, Redman CW. The effect ofplacental syncytiotrophoblast microvillous membranes from normaland pre-eclamptic women on the growth of endotelial cells invitro. Br J Obstet Gynaecol 1993; 100: 943–949.

  64. Germain SJ, Sacks GP, Soorana SR, Sargent IL, Redman CW.Systemic inflammatory priming in normal pregnancy and preeclampsia:the role of circulating syncytiotrophoblast microparticles.J Immunol 2007; 178: 5949–5956.

  65. Sabapatha A, Gercel-Taylor C, Taylor DD. Specific isolation of placenta-derived exosomes from the circulation of pregnant womenand their immunoregulatory consequences. Am J Reprod Immunol2006; 56: 345–355.

  66. Vaughan JE, Walsh SW. Activation of NF-κB in Placentas of Womenwith Preeclampsia. Hypertens Pregnancy 2012; 31(2): 243–251.

  67. Seung SM, Romero R, Lee YJ, Park IS, Park CW, Bo Yoon BH.Systemic inflammatory stimulation by microparticles derived fromhypoxic trophoblast as a model for inflammatory response in Preeclampsia.American Journal of Obstetrics & Gynecology 2012;207: 337.e1-8.

  68. Echeverri NP, Mockus IS. Factor nuclear kB (NF-kB): Signalosomay su importancia en enfermedades inflamatorias y cáncer.Rev. Fac. Med 2008; 56 (2): 135.

  69. Nadeau-Vallée M, Obari D, Palacios J, et al. Sterile inflammationand pregnancy complications: a review. Reproduction. 2016 Dec;152(6):R277-R292. DOI: 10.1530/REP-16-0453.

  70. Schaefer L. Complexity of danger: the diverse nature of damage-associated molecular patterns. J Biol Chem. 2014 Dec19;289(51):35237-45. doi: 10.1074/jbc.R114.619304.

  71. Goulopoulou S, Davidge ST. Molecular mechanisms of maternalvascular dysfunction in preeclampsia. Send to Trends Mol Med.2015 Feb;21(2):88-97. doi: 10.1016/j.molmed.2014.11.009.




2020     |     www.medigraphic.com